Across TCGA pan-cancer cohorts, MYO5A mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MYO5A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MYO5A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MYO5A is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.

CCRCC, HNSC, and COAD are the cancer types where MYO5A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYO5A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	+0.415	<.001	12	view →
HNSC	Male	All	+0.654	<.001	11	view →
COAD	Female	III,IV	−0.339	<.001	9	view →
LSCC	All	All	+0.121	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MYO5A RNA expression & survival · all MYO5A data types